Brief: Cognition Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update

Cognition Therapeutics

04/05/2023 22:06

May 4 (Reuters) - Cognition Therapeutics Inc  CGTX.O :
    * COGNITION THERAPEUTICS REPORTS FIRST QUARTER 2023
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * Q1 LOSS PER SHARE $0.21
    * COGNITION THERAPEUTICS - COMPLETED ENROLLMENT FOR PHASE 2
SEQUEL
TRIAL IN MILD-TO-MODERATE ALZHEIMER'S DISEASE (AD); TOPLINE
RESULTS EXPECTED 2Q 2023
    * SHINE (AD) TRIAL CURRENTLY ENROLLING PATIENTS WITH FIRST
PATIENT
IN SPAIN ENROLLED, EXPECT FULL ENROLLMENT BY END OF 2023
    * EXTENDED CASH RUNWAY INTO SECOND HALF OF 2024 BASED ON
CASH AND
CASH EQUIVALENTS AS OF MARCH 31, 2023
    * CASH AND CASH EQUIVALENTS ON MARCH 31, 2023, WERE
APPROXIMATELY
$38.8 MILLION
    * Q1 EARNINGS PER SHARE VIEW $-0.18 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX1znQCw 
Further company coverage:  CGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))